Adaptimmune Therapeutics PLC

Commercial-stage cell-therapy company with first-in-class approved TECELRA but explicit going-concern doubt and deep losses.

Strengths

• First engineered T-cell therapy approved for a solid tumor; lete-cel launch (2026) and breakthrough designation
• Revenue growth 195% (86th pct) and 99.9% gross margin as commercialization begins

Risks

• Auditor going-concern doubt; net margin -40%, deeply negative ROE (3.8th pct) on 4.2x debt/equity
• 29% headcount cut and strategic-review/cash strain despite 8 quarters runway

Notable findings

• Going concern● Although our financial statements have been prepared on a going concern basis, there is substantial doubt about our ability to continue as a going concern
• High leverageHigh leverage (debt/equity 4.24)
• Net lossNet loss (net margin -39.8%)
• Cash burnNegative free cash flow (-74.1M)
• Chronic dilutionShare count +15%/yr over 3y (dilution, book value/share -96%)
• Strong balance sheetStrong balance sheet — $152M cash & investments, ~8 quarters of runway